Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

7(87.5%)

N/A

1(12.5%)

8Total

Phase 1(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00525733Not ApplicableCompleted

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Role: collaborator

NCT00252148Phase 1Completed

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Role: collaborator

NCT00249106Phase 1Completed

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults

Role: collaborator

NCT01292174Phase 1Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

Role: collaborator

NCT00703586Phase 1Completed

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Role: collaborator

NCT00219934Completed

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

Role: collaborator

NCT00545987Phase 1Completed

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

Role: collaborator

NCT00006209Phase 1Unknown

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

Role: lead

NCT00002104Phase 1Completed

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

Role: lead

All 9 trials loaded